• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微粒系统增强抗青光眼药物药效学的荟萃分析研究

Particulate Systems in the Enhancement of the Antiglaucomatous Drug Pharmacodynamics: A Meta-Analysis Study.

作者信息

Hathout Rania M

机构信息

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.

出版信息

ACS Omega. 2019 Dec 16;4(26):21909-21913. doi: 10.1021/acsomega.9b02895. eCollection 2019 Dec 24.

DOI:10.1021/acsomega.9b02895
PMID:31891069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6933800/
Abstract

Glaucoma is a very serious disease that can lead to blindness in severe cases. In an attempt to increase the efficacy of the drugs used in treating this disease, many particulate systems (micro/nano and lipid-based/nonlipid-based) have been exploited. In this study, the meta-analysis approach was implemented in order to explore the published studies and extract the literature-based evidence (proof-of-concept studies = 16) that the particulate systems increase the efficiency of the investigated intraocular pressure drugs as demonstrated by the increase in the area under effect curve. Comparison of micron particles versus nanoparticles on the one hand and lipid-based versus nonlipid-based on the other hand, as subgroups of the meta-analysis, was also included in the study where the latter comparison led to insignificant differences, whereas the former has proven the superiority of the nanoparticles over the micronized counterparts.

摘要

青光眼是一种非常严重的疾病,在严重情况下可导致失明。为了提高用于治疗这种疾病的药物的疗效,人们开发了许多微粒系统(基于微/纳米以及基于脂质/非脂质)。在本研究中,采用了荟萃分析方法来探究已发表的研究,并提取基于文献的证据(概念验证研究 = 16 项),即微粒系统可提高所研究的眼内压药物的效率,这一点通过效应曲线下面积的增加得以证明。作为荟萃分析的子组,还对一方面的微米颗粒与纳米颗粒以及另一方面的基于脂质与基于非脂质进行了比较,该研究中后一种比较结果无显著差异,而前一种比较已证明纳米颗粒优于微粉化对应物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cecb/6933800/10628101d3f5/ao9b02895_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cecb/6933800/bd676175e246/ao9b02895_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cecb/6933800/10628101d3f5/ao9b02895_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cecb/6933800/bd676175e246/ao9b02895_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cecb/6933800/10628101d3f5/ao9b02895_0002.jpg

相似文献

1
Particulate Systems in the Enhancement of the Antiglaucomatous Drug Pharmacodynamics: A Meta-Analysis Study.微粒系统增强抗青光眼药物药效学的荟萃分析研究
ACS Omega. 2019 Dec 16;4(26):21909-21913. doi: 10.1021/acsomega.9b02895. eCollection 2019 Dec 24.
2
[Efficacy of latanoprost versus travoprost assessed by daily intraocular pressure curve].通过每日眼压曲线评估拉坦前列素与曲伏前列素的疗效
Arq Bras Oftalmol. 2009 Jan-Feb;72(1):13-7. doi: 10.1590/s0004-27492009000100003.
3
[Preoperative therapy switch before glaucoma filtration surgery : Influence of the systemic antiglaucomatous and local antiphlogistic therapy on the intraocular pressure].青光眼滤过手术前的术前治疗转换:全身抗青光眼治疗和局部抗炎治疗对眼压的影响
Ophthalmologe. 2017 Jul;114(7):632-638. doi: 10.1007/s00347-016-0396-4.
4
Estimating dermal transfer of copper particles from the surfaces of pressure-treated lumber and implications for exposure.从经压力处理的木材表面估算铜颗粒的皮肤转移及其对暴露的影响。
Sci Total Environ. 2016 Apr 1;548-549:441-449. doi: 10.1016/j.scitotenv.2015.12.108. Epub 2016 Jan 28.
5
6
[Continuous intraocular pressure measurement over several days with the Codman Microsensor--a case report].[使用科德曼微传感器连续数天测量眼压——病例报告]
Klin Monbl Augenheilkd. 1999 Sep;215(3):186-96. doi: 10.1055/s-2008-1034697.
7
Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.回复拉赫曼·希里博士的来信:职业群体中的自杀这一具有挑战性的话题。
Scand J Work Environ Health. 2018 Jan 1;44(1):108-110. doi: 10.5271/sjweh.3698. Epub 2017 Dec 8.
8
[The circadian effects of antiglaucomatous drugs].[抗青光眼药物的昼夜节律效应]
J Fr Ophtalmol. 2004 Sep;27 Spec No 2:2S33-2S38.
9
PLA micro- and nano-particles.聚乳酸微颗粒和纳米颗粒。
Adv Drug Deliv Rev. 2016 Dec 15;107:176-191. doi: 10.1016/j.addr.2016.05.020. Epub 2016 Jun 1.
10
[Molecular genetic aspects of glaucoma pathogenesis].[青光眼发病机制的分子遗传学方面]
Vestn Oftalmol. 2013 Jul-Aug;129(4):76-82.

引用本文的文献

1
Current Innovations in Intraocular Pressure Monitoring Biosensors for Diagnosis and Treatment of Glaucoma-Novel Strategies and Future Perspectives.当前眼压监测生物传感器在青光眼诊断和治疗中的创新——新策略和未来展望。
Biosensors (Basel). 2023 Jun 18;13(6):663. doi: 10.3390/bios13060663.
2
Meta-Analysis: A Convenient Tool for the Choice of Nose-to-Brain Nanocarriers.Meta分析:一种用于选择鼻脑纳米载体的便捷工具。
Bioengineering (Basel). 2022 Nov 3;9(11):647. doi: 10.3390/bioengineering9110647.
3
Augmented in vitro and in vivo Profiles of Brimonidine Tartrate Using Gelatinized-Core Liposomes.

本文引用的文献

1
Exploring optimized methoxy poly(ethylene glycol)-block-poly(ε-caprolactone) crystalline cored micelles in anti-glaucoma pharmacotherapy.探索优化的甲氧基聚乙二醇-嵌段-聚(ε-己内酯)结晶核胶束在抗青光眼药物治疗中的应用。
Int J Pharm. 2019 Jul 20;566:573-584. doi: 10.1016/j.ijpharm.2019.06.011. Epub 2019 Jun 6.
2
Gelatin Nanoparticles.明胶纳米颗粒
Methods Mol Biol. 2019;2000:71-78. doi: 10.1007/978-1-4939-9516-5_6.
3
Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment.混合脂质体/羟丙基甲基纤维素系统中的渗透保护剂作为青光眼的潜在治疗方法
使用明胶化核脂质体增强酒石酸溴莫尼定的体外和体内特性。
Int J Nanomedicine. 2022 Jun 25;17:2753-2776. doi: 10.2147/IJN.S370192. eCollection 2022.
4
Do Polymeric Nanoparticles Really Enhance the Bioavailability of Oral Drugs? A Quantitative Answer Using Meta-Analysis.聚合物纳米颗粒真的能提高口服药物的生物利用度吗?基于荟萃分析的定量解答。
Gels. 2022 Feb 14;8(2):119. doi: 10.3390/gels8020119.
5
Recent Research in Ocular Cystinosis: Drug Delivery Systems, Cysteamine Detection Methods and Future Perspectives.眼部胱氨酸病的最新研究:药物递送系统、半胱胺检测方法及未来展望
Pharmaceutics. 2020 Dec 3;12(12):1177. doi: 10.3390/pharmaceutics12121177.
Polymers (Basel). 2019 May 28;11(6):929. doi: 10.3390/polym11060929.
4
Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study.原前体凝胶衍生的尼莫司汀:一种持续改善酒石酸溴莫尼定眼部递药的方法;制剂、体外特征及体内药效学研究。
Drug Deliv. 2019 Dec;26(1):509-521. doi: 10.1080/10717544.2019.1609622.
5
Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication.胶凝核心脂质体:新型马来酸噻吗洛尔青光眼药物研制的新“特洛伊木马”。
Int J Pharm. 2019 Feb 10;556:192-199. doi: 10.1016/j.ijpharm.2018.12.015. Epub 2018 Dec 12.
6
Formulation and Characterization of Carvedilol Leciplex for Glaucoma Treatment: In-Vitro, Ex-Vivo and In-Vivo Study.用于青光眼治疗的卡维地洛脂质复合物的制剂与表征:体外、离体和体内研究
Pharmaceutics. 2018 Oct 21;10(4):197. doi: 10.3390/pharmaceutics10040197.
7
Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: Augmented in-vivo efficacy and safe histological profile.探索明胶纳米粒作为马来酸噻吗洛尔的新型纳米载体:增强体内疗效和安全的组织学特征。
Int J Pharm. 2018 Jul 10;545(1-2):229-239. doi: 10.1016/j.ijpharm.2018.04.059. Epub 2018 Apr 27.
8
Gelatinized-core liposomes: Toward a more robust carrier for hydrophilic molecules.胶束核心脂质体:向更稳健的亲水分子载体发展。
J Biomed Mater Res A. 2017 Nov;105(11):3086-3092. doi: 10.1002/jbm.a.36175. Epub 2017 Aug 21.
9
Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma.新型复合药物输送系统中释放的溴莫尼定用于治疗青光眼的持续释放。
ACS Appl Mater Interfaces. 2017 Mar 8;9(9):7990-7999. doi: 10.1021/acsami.6b16509. Epub 2017 Feb 27.
10
Studying the effect of physically-adsorbed coating polymers on the cytotoxic activity of optimized bisdemethoxycurcumin loaded-PLGA nanoparticles.研究物理吸附的包衣聚合物对优化的载双去甲氧基姜黄素聚乳酸-羟基乙酸共聚物纳米粒细胞毒性活性的影响。
J Biomed Mater Res A. 2017 May;105(5):1433-1445. doi: 10.1002/jbm.a.36028. Epub 2017 Feb 24.